In patients with type 2 diabetes, the risk for chronic kidney disease differed among users of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylurea.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback